GLP-1 Receptor Agonists in Diabetic Kidney Disease: From Clinical Outcomes to Mechanisms

Frontiers in Pharmacology
Daiji Kawanami, Yuichi Takashi

Abstract

Diabetic Kidney Disease (DKD) is the leading cause of end stage renal disease (ESRD) worldwide. Glucagon-like peptide 1 receptor agonists (GLP-1RAs) are now widely used in the treatment of patients with type 2 diabetes (T2D). A series of clinical and experimental studies demonstrated that GLP-1RAs have beneficial effects on DKD, independent of their glucose-lowering abilities, which are mediated by natriuresis, anti-inflammatory and anti-oxidative stress properties. Furthermore, GLP-1RAs have been shown to suppress renal fibrosis. Recent clinical trials have demonstrated that GLP-1RAs have beneficial effects on renal outcomes, especially in patients with T2D who are at high risk for CVD. These findings suggest that GLP-1RAs hold great promise in preventing the onset and progression of DKD. However, GLP-1RAs have only been shown to reduce albuminuria, and their ability to reduce progression to ESRD remains to be elucidated. In this review article, we highlight the current understanding of the clinical efficacy and the mechanisms underlying the effects of GLP-1RAs in DKD.

References

Jul 14, 1998·Nature Genetics·P J SchultheisG E Shull
Jun 8, 2004·The Journal of Clinical Endocrinology and Metabolism·Jean-Pierre GutzwillerChristoph Beglinger
Sep 25, 2009·American Journal of Physiology. Renal Physiology·Luciene R Carraro-LacroixAdriana C C Girardi
May 20, 2011·American Journal of Physiology. Renal Physiology·Renato O CrajoinasAdriana C C Girardi
Aug 15, 2012·Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology·Wenbin LiDongmei Xu
Mar 7, 2013·The Journal of Clinical Endocrinology and Metabolism·Jeppe SkovJens Sandahl Christiansen
Feb 22, 2014·Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology·Wen-Wei XuYao-Ming Xue
Sep 10, 2014·Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology·Cheng WangTanqi Lou
Mar 31, 2015·Journal of the American Society of Nephrology : JASN·Jae Wook LeeMark A Knepper
Aug 19, 2015·JAMA : the Journal of the American Medical Association·Melanie J DaviesRalph A DeFronzo
Oct 9, 2015·American Journal of Physiology. Renal Physiology·Lívia X S FarahAdriana C C Girardi
Dec 3, 2015·The New England Journal of Medicine·Marc A PfefferUNKNOWN ELIXA Investigators
Dec 5, 2015·Diabetes, Obesity & Metabolism·Marcel H A MuskietDaniël H van Raalte
Apr 21, 2016·Histology and Histopathology·Daiji KawanamiKazunori Utsunomiya
Jun 14, 2016·The New England Journal of Medicine·Steven P MarsoUNKNOWN LEADER Trial Investigators
Jun 15, 2016·The New England Journal of Medicine·Christoph WannerUNKNOWN EMPA-REG OUTCOME Investigators
Jul 28, 2016·Biochemical and Biophysical Research Communications·Nana LiWenyan Niu
Sep 17, 2016·The New England Journal of Medicine·Steven P MarsoUNKNOWN SUSTAIN-6 Investigators
Oct 19, 2016·Diabetes, Obesity & Metabolism·Bernt J von ScholtenPeter Rossing
Jul 18, 2017·European Journal of Internal Medicine·María Dolores García de LucasJulián Olalla Sierra
Aug 31, 2017·The New England Journal of Medicine·Johannes F E MannUNKNOWN LEADER Steering Committee and Investigators
Sep 5, 2017·Nature Reviews. Nephrology·Marcel H A MuskietDaniël H van Raalte
Sep 15, 2017·The New England Journal of Medicine·Rury R HolmanUNKNOWN EXSCEL Study Group
Nov 16, 2017·Biochemical and Biophysical Research Communications·Weiqin YinJinning Lou
Mar 14, 2018·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Ya-Kun LiJun Yang
Jun 26, 2018·The Lancet. Diabetes & Endocrinology·Vlado PerkovicBruce Neal
Aug 16, 2018·The New England Journal of Medicine·Aidin RawshaniSoffia Gudbjörnsdottir
Oct 26, 2018·American Journal of Physiology. Renal Physiology·Lennart TonneijckDaniël H van Raalte

❮ Previous
Next ❯

Citations

Dec 17, 2020·International Journal of General Medicine·Mohamed Hassan ElnaemEjaz Cheema
Feb 11, 2021·Antioxidants·Daiji KawanamiMakito Tanabe
Jul 31, 2021·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Junmin WangGuang Ji
Jul 21, 2021·Nature Reviews. Nephrology·Eoin BrennanCatherine Godson
Apr 22, 2021·Transplant International : Official Journal of the European Society for Organ Transplantation·Lale A ErtugluMehmet Kanbay
Aug 28, 2021·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Jared BerndtSok Cheon Pak

❮ Previous
Next ❯

Methods Mentioned

BETA
X-ray

Clinical Trials Mentioned

NCT03819153

Software Mentioned

ELIXA
LEADER
DELIGHT
FLOW
REWIND

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Related Papers

Endocrine Connections
Christine Rode AndreasenTina Vilsbøll
Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [and] German Diabetes Association
Lawrence A Leiter, Michael A Nauck
Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy
Philip A LevinSeoyoung C Kim
© 2021 Meta ULC. All rights reserved